These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 30662312)
1. Shariare MH; Altamimi MA; Marzan AL; Tabassum R; Jahan B; Reza HM; Rahman M; Ahsan GU; Kazi M Saudi Pharm J; 2019 Jan; 27(1):96-105. PubMed ID: 30662312 [TBL] [Abstract][Full Text] [Related]
2. Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach. Marzan AL; Tabassum R; Jahan B; Asif MH; Reza HM; Kazi M; Alshehri SM; de Matas M; Shariare MH Curr Drug Deliv; 2018; 15(5):672-685. PubMed ID: 29359667 [TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of amorphous ezetimibe nanosuspensions intended for enhancement of oral bioavailability. Thadkala K; Nanam PK; Rambabu B; Sailu C; Aukunuru J Int J Pharm Investig; 2014 Jul; 4(3):131-7. PubMed ID: 25126526 [TBL] [Abstract][Full Text] [Related]
4. Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability. Parmar K; Shah J Curr Drug Deliv; 2021; 18(8):1148-1161. PubMed ID: 33438540 [TBL] [Abstract][Full Text] [Related]
5. Development of a Resveratrol Nanosuspension Using the Antisolvent Precipitation Method without Solvent Removal, Based on a Quality by Design (QbD) Approach. Kuk DH; Ha ES; Ha DH; Sim WY; Lee SK; Jeong JS; Kim JS; Baek IH; Park H; Choi DH; Yoo JW; Jeong SH; Hwang SJ; Kim MS Pharmaceutics; 2019 Dec; 11(12):. PubMed ID: 31861173 [TBL] [Abstract][Full Text] [Related]
6. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology. Gajera BY; Shah DA; Dave RH Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724 [TBL] [Abstract][Full Text] [Related]
7. Study of Formulation and Process Variables for Optimization of Piroxicam Nanosuspension Using 3 Alhamhoom Y; Honmane SM; Hani U; Osmani RAM; Kandasamy G; Vasudevan R; Paramshetti S; R Dudhal R; K Kengar N; Charde MS Polymers (Basel); 2023 Jan; 15(3):. PubMed ID: 36771784 [TBL] [Abstract][Full Text] [Related]
8. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation. Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401 [TBL] [Abstract][Full Text] [Related]
9. 24 Factorial Design Formulation Optimization and In vitro Characterization of Desloratadine Nanosuspension Prepared Using Antisolvent Precipitation. El-Sebaiy MT; Alyami MH; Alyami HS; Kamal MA; Eissa N; Balata G; El-Nahas H Curr Drug Deliv; 2024 Jun; ():. PubMed ID: 38867526 [TBL] [Abstract][Full Text] [Related]
10. Comparative study on stabilizing ability of food protein, non-ionic surfactant and anionic surfactant on BCS type II drug carvedilol loaded nanosuspension: Physicochemical and pharmacokinetic investigation. Geng T; Banerjee P; Lu Z; Zoghbi A; Li T; Wang B Eur J Pharm Sci; 2017 Nov; 109():200-208. PubMed ID: 28811130 [TBL] [Abstract][Full Text] [Related]
11. Nanoprecipitation with sonication for enhancement of oral bioavailability of furosemide. Sahu BP; Das MK Acta Pol Pharm; 2014; 71(1):129-37. PubMed ID: 24779201 [TBL] [Abstract][Full Text] [Related]
12. Formulation and Characterization of Ursodeoxycholic Acid Nanosuspension Based on Bottom-Up Technology and Box-Behnken Design Optimization. Boscolo O; Flor S; Salvo L; Dobrecky C; Höcht C; Tripodi V; Moretton M; Lucangioli S Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631251 [TBL] [Abstract][Full Text] [Related]
13. Enhancement of solubility, antioxidant ability and bioavailability of taxifolin nanoparticles by liquid antisolvent precipitation technique. Zu Y; Wu W; Zhao X; Li Y; Wang W; Zhong C; Zhang Y; Zhao X Int J Pharm; 2014 Aug; 471(1-2):366-76. PubMed ID: 24882039 [TBL] [Abstract][Full Text] [Related]
14. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement. Thakkar HP; Patel BV; Thakkar SP J Pharm Bioallied Sci; 2011 Jul; 3(3):426-34. PubMed ID: 21966165 [TBL] [Abstract][Full Text] [Related]
15. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design. Kassem MAA; ElMeshad AN; Fares AR AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564 [TBL] [Abstract][Full Text] [Related]
16. Quality by design-based optimization of formulation and process parameters for berberine nanosuspension for enhancing its dissolution rate, bioavailability, and cardioprotective activity. Alsabeelah N; Kumar V J Food Biochem; 2022 Oct; 46(10):e14361. PubMed ID: 35929374 [TBL] [Abstract][Full Text] [Related]
17. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach. Karakucuk A; Celebi N; Teksin ZS Eur J Pharm Sci; 2016 Dec; 95():111-121. PubMed ID: 27181836 [TBL] [Abstract][Full Text] [Related]
18. Preparation and Characterization of Nanosuspension of Aprepitant by H96 Process. Kalvakuntla S; Deshpande M; Attari Z; Kunnatur B K Adv Pharm Bull; 2016 Mar; 6(1):83-90. PubMed ID: 27123422 [TBL] [Abstract][Full Text] [Related]
19. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability. Jain S; Reddy VA; Arora S; Patel K Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488 [TBL] [Abstract][Full Text] [Related]
20. Increase in Dissolution Rate of Zotepine via Nanomilling Process - Impact of Dried Nanocrystalline Suspensions on Bioavailability. Parmar K; Oza K AAPS PharmSciTech; 2021 Dec; 23(1):20. PubMed ID: 34907489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]